ED
AZN icon

Exane Derivatives’s AstraZeneca AZN Stock Holding History

Exane Derivatives’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,577
Closed -$731K – 577
2017
Q2 		$789K Sell
11,577
-29,173
-72% -$1.91M 0.17% 100
2017
Q1 		$2.54M Sell
40,750
-36,823
-47% -$2.14M 0.57% 58
2016
Q4 		$4.24M Sell
77,573
-45,065
-37% -$2.56M 0.84% 21
2016
Q3 		$8.06M Buy
+122,638
New +$8.02M 1.21% 26
2015
Q1 		– Sell
-1,597
Closed -$111K – 519
2014
Q4 		$112K Buy
+1,597
New +$114K 0.02% 274

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Exane Derivatives's AZN Position: Q3 2017 in Review

Exane Derivatives sold out of AstraZeneca (AZN) in Q3 2017, closing a stake of 11,577 shares — an estimated $731K sold.

Exane Derivatives first reported a position in AZN in Q4 2014 and held it in 5 quarters. The position peaked at $8.06M in Q3 2016. 455 funds tracked by Wall St. Rank hold AZN as of Q3 2017.

  • Exane Derivatives reported no remaining AstraZeneca position as of Q3 2017 after selling out during the quarter.
  • Exane Derivatives sold 11,577 AstraZeneca shares in Q3 2017, an estimated $731K.
  • Exane Derivatives first reported a position in AstraZeneca in Q4 2014 and held it in 5 quarters.
  • Exane Derivatives's AstraZeneca position peaked at $8.06M in Q3 2016.
  • 455 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2017.

Based on Exane Derivatives's 13F filing for Q3 2017, filed 18 Oct 2017.